Skip to main content

Our End User License Agreement has been updated. Click here to learn more

Product Performance

Eversense Sensor

Strong Accuracy and Outcomes Across All Major Indicators

  • A demonstrated 8.5% Mean Absolute Relative Difference (MARD)1
  • Fluorescence-based technology unaffected by ascorbic acid and acetaminophen2
  • Excellent accuracy in the 2.2-3.3 mmol/L hypoglycemic range (86.5% within 15/15 YSI)3
  • Sensor adherence of 23+ hours per day4,5
  • A clinically meaningful HbA1c reduction across major studies3-5

For more information on Eversense’s safety and performance, contact us to get a copy of our Outcomes Summary.

Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. Sensor Chemical Interference Screen Summary Report. Senseonics internal reporting, USA, July 2015. Eversense FDA Summary of Safety and Effectiveness Data (SSED)  Data on file. Senseonics 2019. PRECISE Supplement. Data on file. Senseonics 2018. Lind M, Diabetes Metab Syndr. 2008;2(4) 282-293. Kropff, J. PRECISE study. Diabetes Care, 40(1), 63-68.

MKT-001296 Rev1